An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1) - Fig 4
- Tarik Asselah (717526)
- Christophe Moreno (798309)
- Christoph Sarrazin (48298)
- Michael Gschwantler (3151779)
- Graham R. Foster (2577061)
- Antonio Craxí (3151770)
- Peter Buggisch (587274)
- Robert Ryan (3151776)
- Oliver Lenz (201764)
- Jane Scott (699073)
- Gino Van Dooren (3151773)
- Isabelle Lonjon-Domanec (799329)
- Michael Schlag (3151782)
- Maria Buti (161144)
Publication date
July 2016
DOIAbstract
<p>Forest plot showing the results of the final multivariate logistic regression analyses of factors associated with <b>[A]</b> SVR12 and <b>[B]</b> viral relapse in patients receiving 12 weeks of treatment.</p
Add to ORKG